Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The United Kingdom introduced meningococcal serogroup C conjugate (MCC) vaccines in 1999, resulting in substantial declines in serogroup C disease and carriage. Here, we measured the age-specific prevalence of serum bactericidal antibodies (SBA) to Neisseria meningitidis serogroup C and immunoglobulin G (IgG) concentrations to serogroups A, C, W-135, and Y in 2,673 serum samples collected in England between 2000 and 2004. We compared the seroprevalence of SBA titers of ≥8 in the postvaccination era with results from an earlier prevaccination study conducted using the same methods. We found that the percentages of individuals with protective SBA titers were higher in 2000 to 2004 in all of the age groups targeted for MCC vaccination. In the postvaccine era, the prevalence of protective titers was high (75%) in children who had recently been offered routine immunization, but this fell to 36% more than 18 months after scheduled immunization. In the cohorts targeted in the catch-up campaign, the percentage achieving SBA titers of ≥8 was higher in children offered the vaccine at ages 5 to 17 years than in children offered the vaccine at ages 1 to 4 years. The geometric mean concentration (GMC) IgG for serogroup C followed a similar pattern, corresponding to the age at and time since scheduled MCC vaccination. Serogroup-specific IgG GMCs for W-135 and Y were low and showed little variation by age. Serogroup A IgG GMCs were higher, possibly reflecting exposure to cross-reacting antigens. Although the incidence of serogroup C disease remains low due to persisting herd effects, population antibody levels to serogroup C meningococci should be monitored so that potentially susceptible age groups can be identified should herd immunity wane.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16725-1 · Cited by 571 · cited 3×
“In September 2006, the United Kingdom routine infant immunization schedule was changed (5) in response to evidence from postlicensure surveillance studies showing that only short-term direct protection is conferred when children are routinely immunized at 2, 3, and 4 months of age with MCC (29) and Hib (23) vaccines.”
Self-citationImpact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Maiden, M. C. J., Ibarz-Pavón, A. B., Urwin, R., Gray, S. J., Andrews, N. J., Clarke, S. C., Walker, A. M., Evans, M. R., Kroll, J. S., Neal, K. R., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/527401 · Cited by 442
Self-citationMaiden, M. C., & Stuart, J. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08679-8 · Cited by 418
Ramsay, M. E., McVernon, J., Andrews, N. J., Heath, P. T., & Slack, M. P. (2003) · The Journal of Infectious Diseases · doi:10.1086/376997 · Cited by 172
Self-citation
Cited by
Trotter, C. L., & Maiden, M. C. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.48 · Cited by 203
Self-citationMeningococcal C conjugate vaccine: the experience in England and Wales
Campbell, H., Borrow, R., Salisbury, D., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.067 · Cited by 168
Self-citationEffectiveness of meningococcal serogroup C vaccine programmes
Borrow, R., Abad, R., Trotter, C., van der Klis, F. R. M., & Vazquez, J. A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.083 · Cited by 88
Self-citation
Metadata
- Authors
- Trotter, C. L., Borrow, R., Findlow, J., Holland, A., Frankland, S., Andrews, N. J., & Miller, E.
- Venue
- Clinical and Vaccine Immunology
- Publisher
- American Society for Microbiology
- Published
- 2008-11
- Volume
- 15
- Issue
- 11
- Pages
- 1694-1698
- ISSN
- 1556-679X (ISSN-L)
- 1556-6811
- OpenAlex
- W2129094433
- Cited by
- 70
- References
- 4
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.